The percentage of CD14low/CD16++ monocytes among total CD14-positive cells in long-standing RA patients (median 7.98% (IQR 3.6 to 9.6), n = 38) was not significantly different from control subjects (median 6.51% (IQR 4.4 to 10.4), n = 40) (p = 0.305; Mann-Whitney U). This evidence concerns the gene FCGR3A and rheumatoid arthritis.